Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
NEW YORK (Reuters Health) – The combination of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) is often prescribed for elderly patients who do not…
NEW YORK (Reuters Health) – Percutaneous balloon angioplasty with stenting of renal artery stenosis (RAS) added to medical therapy reduces the need for antihypertensive medication slightly, but otherwise…
NEW YORK (Reuters Health) – Current evidence is still inconclusive as to whether patients with chronic kidney disease (CKD) may benefit from aggressive blood pressure control, according to…
NEW YORK (Reuters Health) – A low-dose regimen of peginterferon, without ribavirin, produces a sustained virologic response in up to 40% of patients with chronic hepatitis C and…
NEW YORK (Reuters Health) — Patients with chronic kidney disease (CKD) who are administered sodium bicarbonate before emergency coronary procedures might be less likely to suffer contrast-induced nephropathy…
NEW YORK (Reuters Health) – In older adults, mean serum levels of 25-hydroxyvitamin D are somewhat higher after a year of taking cholecalciferol (vitamin D3) compared to ergocalciferol…
NEW YORK (Reuters Health) – In patients with chronic kidney disease (CKD), an impaired platelet response clopidogrel independently contributes to worse outcomes after percutaneous coronary intervention (PCI), a…
NEW YORK (Reuters Health) – Nephron-sparing surgery is linked to better survival than radical nephrectomy for renal cell carcinoma, even among patients over age 80, study findings show.…
NEW YORK (Reuters Health) – After a first myocardial infarction, treatment with a calcium-channel blocker (CCB) does not appear to diminish the efficacy of clopidogrel, according to results…
NEW YORK (Reuters Health) – Putting patients on dialysis before they’re symptomatic offers no survival benefit; on the contrary, it may increase their risk of death, according to…
